VN September 2021

Vetnews | September 2021 15 Valley FarmAnimal Hospital is the first hospital to offer dedicated renal replacement therapy in dogs The Valley Farm Animal Hospital haemodialysis team lead by Dr Gareth Zeiler. From left to right: Dr Marinell Breytenbach, Dr Gareth Zeiler, Sr Stephanie Rotherham, Sr Bianca Steyn and Dr Anthea Michaletos Renal replacement therapy, also known as renal dialysis or haemodialysis, has been available as a therapy for dogs and cats since the 1980s. This therapy has been available in academic hospitals and referral practices in northern America and Europe where there is a teamof dedicated personnel specifically trained in this extracorporeal therapy. In Africa, perceived cost constraints and no specialisation in emergency and critical care have likely limited the progress of making this treatment available to veterinarians. Sporadic cases, over the last two decades, where dogs have been taken to human renal dialysis centres for treatment, have been anecdotally mentioned. However, logistics and availability of time at these centres limit its routine use in veterinary medicine – that is until now. Valley Farm Animal Hospital would like to introduce renal replacement therapy as a treatment option for dogs. Renal replacement therapy, very briefly, involves the removal of blood from the patient which flows within an extracorporeal circuit, through a dialyser and then returned to the patient. The dialyser acts as a kidney and assumes the function of removing toxins that would otherwise have been removed by a functional kidney. Many renal toxins have different molecular weights. Renal replacement therapy targets the removal of small and medium-size toxins that are less than40 kDa in sizewhich is smaller thanalbumin (68 kDa). It is not practical to measure all renal toxins during therapy, thus blood urea nitrogen (BUN) is the toxin most often used to monitor therapy adequacy. It is assumed that if BUN is removed effectively, then the other renal toxins shouldalsobe removed. Dogs that are suffering fromacutekidney injuryand have oliguria or anuria could be unresponsive to fluid and diuretic therapy. If there is no response to initial therapy within the first 12 hours, then these patients are at a high risk of mortality. These patients require intermittent renal replacement therapy urgently. This therapy not only rids the body of toxins but assists with balancing the blood volume and acid-base status. Dogs can die from an acute kidney injury before the renal tissue has time to heal, thus this therapy buys time for healing, giving the kidneys a chance to return to adequate function. These patients require intermittent renal replacement therapy for up to 2 weeks. Therapy for chronic renal failure can also be done, but this would require a dedicated and discerning dog owner to commit to, at least, twice or thrice weekly treatments. Intermittent renal replacement therapy is not limited to the management of a patient with acute kidney injury but can be used in patients, for example, with hypervolaemia, immune-mediated diseases and acute intoxication. Hypervolaemia can develop in dogs with kidney injury or failure and heart failure, among other less frequently diagnosed disease processes. The common clinical manifestation of hypervolaemia is distended jugular veins, dyspnoea and cavity effusions. Medical therapy includes the use of diuretics, however, patients that do not respond to diuretic therapy are in danger of developing pulmonary oedema, which could be life-threatening. The dialysis machine can be used to actively remove the excess fluid volume within minutes in an attempt to mitigate the development of life- threatening pulmonary oedema. The dialysis machine does not deplete electrolytes, glucose or albumin concentrations and allows the patient a chance to stabilise during a life-threatening event like pulmonary oedema. After treatment, a cardiac patient with congestive heart failuremight require adjustments to chronic drug therapy to minimize the risk of developing pulmonary oedema again. Immune-mediated diseases, like immune-mediated thrombocytopaenia (IMTP) develops for several reasons and is treatedusing immune-suppressive doses of steroids and drugs like azathioprine and treating an underlying cause (usually tickborne diseases in dogs, or cancer). Sometimes, IMPT occurs as an isolated event and once medically managed, the dog rarely develops another episode. However, dogs that have repeated events or who do not respond with an increase in thrombocytes within 12 hours of medical management are at risk of mortality. These patients could benefit from plasma exchange therapy. In this therapy, the patient’s blood is sent through the extracorporeal circuit of the dialysis machine and the plasma is sieved through a special filter and discarded. Either fresh frozen plasma or an isotonic crystalloid is returned to the patient to maintain their blood volume. Ridding the patient from its plasma allows them an opportunity to gain control of the response of their immune system and to prevent further destruction of their thrombocytes. Acute intoxications could be accidental (dogs eating medicinal or illicit recreational drugs etc.) or malicious (aldicarb etc.).The first treatment option is to decontaminate (if possible) and administer an intravenous bolus of lipid emulsion and perhaps starting activated charcoal therapy. When these interventions do not work and the patient does not improve then renal dialysis using either a dialyser alone or with a charcoal filter should be considered as an emergent therapy. Some intoxications, such as anti-freeze ingestion, do not respond well to medical management and renal dialysis should be considered as a first option treatment. Article >>> 16

RkJQdWJsaXNoZXIy OTc5MDU=